At the Cancer Center at Illinois (CCIL), researchers are leveraging advanced imaging techniques to study drug-tolerant cancer cells, which often survive chemotherapy and contribute to treatment failure. Led by Yang Liu and Chitra Subramanian, the project titled 'Multiscale high-content imaging to identify molecular signatures in drug-tolerant cancer cells' focuses on understanding these persister cells, particularly in head and neck squamous cell carcinoma (HNSCC). The research employs a multiscale imaging platform that integrates super-resolution chromatin imaging and high-content multiplexed fluorescence imaging to detect changes in cancer cells during treatment. Liu emphasized that therapy-resistant cells exhibit distinct changes in their epigenetic organization and behavior, which can be captured through imaging. The project aims to identify reliable molecular, structural, and spatial signatures of therapeutic resistance, potentially leading to predictive biomarkers that can inform treatment strategies. The CCIL Planning Grant has already enabled significant advancements, including improved imaging methods and tissue-level validation, moving the research closer to practical applications in precision medicine. Liu envisions this work as part of a broader initiative to develop clinically useful imaging platforms that can identify aggressive tumor states earlier, ultimately enhancing treatment selection and supporting precision oncology.